CRISIL reaffirms Mankind Pharma at AA

What happened

Mankind Pharma (BSE: MANKIND) informed the stock exchanges on 29 October 2026 at 08:26 PM that CRISIL has reaffirmed its credit rating at AA.

Company snapshot

Mankind Pharma is a large-cap company in the Healthcare sector, with a market value of about ₹1.02 lakh crore.

The stock last traded at ₹2,469.3, against a 52-week range of ₹1,909.7–₹2,642 (6.5% below the high).

Before this filing the shares had moved +2.2% over the month and −3.3% over three months. Average daily turnover over the last 20 sessions was about ₹173 crore.

Promoters held 72.62% at the end of Q2 FY27. Foreign institutions owned 9.37% and domestic institutions 15.56%.

What history shows

BCEIE has no earlier credit rating filing from this company on record since May 2026.

Across 32 similar disclosures by other Healthcare companies, shares moved −0.0% on average the next day and +1.3% over five days; 56% of them rose the next day.

Market-wide, 1,362 credit rating filings with an impact score of 50 or more saw an average next-day move of +0.1%, with 46% rising.

Past reactions describe what happened before; they are not a forecast.

What to watch

• Whether other agencies take a similar view on the company's credit.

In the news

Recent coverage elsewhere (links open the original publisher):

• Mankind Pharma to acquire 70% stake in Armed Cell Therapeutics for EUR 48 million — Express Pharma, 16 Oct 2026
• Mankind Pharma Share Price Today | BO: MNKI — Investing.com India, 26 Oct 2026
• Mankind enters CAR-T contest with ₹500 cr Armed Cell Therapeutics buyout — pharma.economictimes.indiatimes.com, 19 Oct 2026
• Mankind Pharma's quarterly profit jumps 39% on strong chronic drug demand — Reuters, 26 Oct 2026
• Earnings Central: Ather Energy turns profitable, Tata Consumer and Mankind Pharma beat Street — LinkedIn, 26 Oct 2026

Source

• Exchange filing (PDF)